ArticlePharmacoEconomics - open2026
Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) is a progressive disease leading to increasing disability. Our previous simulation model estimated lifetime impacts of MS on quality of life and associated economic costs but was limited by small cohort input data and simplistic structure.
objectiveThe aim was to improve our previous model by incorporating more granular disease states, improving the accuracy of input data using a large MS cohort, and including contemporary cost and health state utility (HSU) inputs, matching the more detailed health states.
methodsA Markov model was developed simulating MS progression from no disability to mild, moderate, and severe disability and death under contemporary treatment patterns. State-specific probabilities of progression, death, relapse, costs, HSUs, and relapse-related disutilities were considered. Life expectancy (LE), quality-adjusted life years (QALYs), and discounted lifetime total costs (2026 Australian dollars) were calculated. Probabilistic sensitivity analysis was performed.
resultsA typical MS cohort of 35-year-old females had a projected mean LE of 44.0 years, 27.3 and 11.3 undiscounted/discounted QALYs, respectively, and lifetime costs of $1,449,597. Compared with the Australian general population, those with MS had 6.8 years lower LE, 15.0 lower undiscounted QALYs, and $1.24 million higher costs. Our updated model showed higher LE and costs but lower QALYs compared with our previous model, due to differences in probability utilities and cost inputs.
conclusionsOur improved model, based on a larger cohort and updated inputs, provides a more nuanced assessment of the impact of MS on LE, QALYs, and costs, with improved face validity. It will be used for the cost-effectiveness analyses of current and future MS interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.